Cargando…
Norbert Bischofberger
Norbert Bischofberger, former CSO of Gilead, discusses antiviral opportunities, Gilead's pivot to oncology and the need for a societal discussion of drug costs.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097445/ https://www.ncbi.nlm.nih.gov/pubmed/29844601 http://dx.doi.org/10.1038/nrd.2018.82 |